drugset / Trial / NCT06501664
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to compare the efficacy and safety of liposome irinotecan +5-FU and irinotecan / irinotecan +5-FU regimens in the second-line treatment of esophageal squamous cell carcinoma (ESCC).
Timeline
- Start
- 2024-08-01
- Primary completion
- 2026-11-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IRINOTECAN | Small molecule | 70 mg/m2 | — |
| Comparator | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | LV | Unknown | 400 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |